Significance of the Higher Molar Dose of Aflibercept 8 mg

Opinion
Video

Panelists discuss how the aflibercept 8 mg higher molecular concentration enables extended durability through increased VEGF binding capacity and longer intraocular drug levels, potentially allowing for less frequent dosing while maintaining efficacy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Video content above is prompted by the following:

      • Aflibercept 8 mg was recently approved for treating age-related macular degeneration and diabetic macular edema. Could you discuss the significance of the higher molar dose?

      Newsletter

      Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

      Subscribe Now!
      Recent Videos
      SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
      SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
      Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
      Modern monitoring strategies remove major barriers to retina care
      (Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
      AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
      3 experts are featured in this series.
      Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies
      Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
      Angiogenesis 2025: The global forecast for AI-driven home OCT
      3 experts are featured in this series.
      Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients
      3 experts are featured in this series.
      Perspectives on the Usefulness of Real-world Data
      3 experts are featured in this series.
      Safety Profile of New Therapies
      3 experts are featured in this series.
      Outcomes with Raricimab and Choosing Between the New Therapies
      3 experts are featured in this series.
      Faricimab Molecular Design and Role of Ang-2
      Related Content
      Health Canada approves aflibercept biosimilar Aflivu

      Health Canada approves aflibercept biosimilar Aflivu

      Sydney M Crago
      July 10th 2025
      Article

      Health Canada approves Aflivu, a biosimilar for retinal diseases, enhancing treatment options and affordability for Canadian patients.

      PHOTON Results and Their Relation to DME Patients in Your Practice

      PHOTON Results and Their Relation to DME Patients in Your Practice

      July 25th 2024
      Podcast

      John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

      A person sits at their laptop with a cup of coffee visible in the foreground. Concept image for instant coffee, AMD, age related macular degeneration, ocular health and instant coffee investigation. Image credit: ©Ljustina – stock.adobe.com

      Patients with high genetic risk of AMD should avoid instant coffee, investigators say

      Lynda Charters
      July 1st 2025
      Article

      Investigators obtained data from genome‐wide association studies to examine the effects of instant coffee consumption

      PULSAR Results and Their Relation to nAMD Patients in Your Practice

      PULSAR Results and Their Relation to nAMD Patients in Your Practice

      July 24th 2024
      Podcast

      John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

      Zeteo Biomedical receives new EU and US patents for its drug delivery technologies

      Zeteo Biomedical receives new EU and US patents for its drug delivery technologies

      Kassi Filkins
      June 11th 2025
      Article

      ZTech-L and ZTech-P, as part of the ZTech portfolio, supports administering therapeutics in both liquid and dry powder formulations

      The Agência de vigilância Sanitária (ANVISA) in Brazil. Concept image for pharmaceutical approval, Lucentis ranibizumab biosimilar ranivisio FYB201. Image credit: ©Rmcarvalhobsb – stock.adobe.com

      Brazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)

      Lynda Charters
      June 5th 2025
      Article

      Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.

      © 2025 MJH Life Sciences

      All rights reserved.